序号 |
标题 |
次数 |
作者 |
发布时间 |
78076 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
113 |
h |
2024-12-19 |
78077 |
CL2A-SN38,cas:1279680-68-0,ADC定制 |
194 |
wyh |
2024-12-19 |
78078 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
98 |
h |
2024-12-19 |
78079 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
172 |
h |
2024-12-19 |
78080 |
MC-MMAF , cas:863971-19-1,ADC定制 |
124 |
wyh |
2024-12-19 |
78081 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
162 |
zyl |
2024-12-19 |
78082 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
108 |
h |
2024-12-19 |
78083 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
115 |
h |
2024-12-19 |
78084 |
Vc-MMAE, cas:646502-53-6,ADC定制 |
164 |
wyh |
2024-12-19 |
78085 |
Azido-PEG4-MMAE |
127 |
zyl |
2024-12-19 |
78086 |
cas:2055024-59-2,Fmoc-PEG2-Val-Cit-PAB-OH |
127 |
zyl |
2024-12-19 |
78087 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin,ADC定制 |
128 |
wyh |
2024-12-19 |
78088 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
84 |
h |
2024-12-19 |
78089 |
cas:1807530-16-0,2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
119 |
zyl |
2024-12-19 |
78090 |
DOTA偶联受体特异性肽 |
134 |
h |
2024-12-19 |
78091 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
124 |
h |
2024-12-19 |
78092 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
125 |
h |
2024-12-19 |
78093 |
ALD-tetra-EG-Osu的介绍 |
146 |
zyl |
2024-12-19 |
78094 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
252 |
h |
2024-12-19 |
78095 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
113 |
h |
2024-12-19 |
78096 |
cas:55750-63-5,Mal-heptanoic NHS ester |
140 |
zyl |
2024-12-19 |
78097 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
121 |
h |
2024-12-19 |
78098 |
cas:663599-10-8,DMAC-SPP |
122 |
zyl |
2024-12-19 |
78099 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
163 |
h |
2024-12-19 |
78100 |
PEG-pGlu(DOTA)8-LA4 |
69 |
h |
2024-12-19 |
78101 |
cas:937025-17-7,2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
158 |
zyl |
2024-12-19 |
78102 |
DOTA-Hyd-TRP PET示踪剂 |
125 |
h |
2024-12-19 |
78103 |
Ga-DOTATOC Ga-DOTA-D-Phe-Tyr-奥曲肽 |
172 |
h |
2024-12-19 |
78104 |
cas:1226371-65-8,N-(2-(2,5-Dimethylphenoxy)ethyl)-4-formylbenzamide |
94 |
zyl |
2024-12-19 |
78105 |
DOTA-ALN DOTA-阿仑膦酸盐 |
103 |
h |
2024-12-19 |
78106 |
氨氯地平DOTA偶联物 DOTA-Amlodipine |
160 |
h |
2024-12-19 |
78107 |
cas:906564-59-8,Propargyl-C2-NHS ester |
108 |
zyl |
2024-12-19 |
78108 |
DOTA-Gp2-EGFR DOTA螯合剂标记结合表皮生长因子受体EGFR靶向Gp2 |
99 |
h |
2024-12-19 |
78109 |
cas:894095-98-8,β-D-glucuronide-pNP-carbonate |
94 |
zyl |
2024-12-19 |
78110 |
DOTA结合肽功能化金纳米粒子 |
108 |
h |
2024-12-19 |
78111 |
90Y-DOTA-Bn 钇-90-DOTA-铃蟾肽 |
141 |
h |
2024-12-19 |
78112 |
cas:85916-13-8,NH-bis(C1-Boc),亚氨基二乙酸二异丁酯 |
137 |
zyl |
2024-12-19 |
78113 |
Anti-CD19 (clone huB4)-Mc-MMAF-ADC分子 |
81 |
zyl |
2024-12-19 |
78114 |
Boc-Val-Cit-PAB-PNP cas:870487-10-8 |
78 |
zyl |
2024-12-19 |
78115 |
cas:2353409-70-6 MMAF-methyl ester |
188 |
zyl |
2024-12-19 |
78116 |
DOTA-ipilimumab 螯合剂DOTA缀合单克隆抗体ipilimumab |
111 |
h |
2024-12-19 |
78117 |
双功能单膦酸Ln-DOTA衍生物 |
125 |
h |
2024-12-19 |
78118 |
Cu-DOTA-阿伦膦酸盐 Cu-DOTA-alendronate |
111 |
h |
2024-12-19 |
78119 |
Mc-3377的介绍 |
94 |
zyl |
2024-12-19 |
78120 |
Endo-BCN-PEG4-Val-Cit-PAB-MMAF的介绍 |
93 |
zyl |
2024-12-19 |